Drug-Conjugates, Glutathione, Screening, HPLC Glutathione (GSH) adducts and consecutive degradation products thereof are indications of reactive intermediates during drug metabolism. As demonstrated with the analgesic SX-PP 16 (4-amino-3,5-dibromacetanilide), however, interactions of a drug with GSH can be detected by labelling the GSH-stores with labelled cysteine, and consecutive administration of the unlabelled drug even at therapeutic doses. The GSH-adducts are sensitively and specifically traced by HPLC, applying column-switching and a combination of diode array-and radioactivity detection. This approach seems to be much more sensitive than a classical GSH-depletion study. The structure of the main metabolite of SX-PP 16 (46% of urinary excretion) was elucidated as 3-bromo-4-amino-5-mercapturyl-acetanilid.
Introduction
Glutathion (GSH) conjugates, and consecutive de gradation products thereof, are severe indications of reactive intermediates during drug metabolism fl, 2], The unambigious detection of such reactives would be of great importance during early stages of drug development. The normally applied GSH-depletion measurements, however, suffer from their poor sen sitivity. This is valid especially as low drug doses are concerned, since the measurement of a small de crease from a huge GSH store is involved. Therefore the rational approach is to trace the products of GSH interaction.
The isolation of such sulfur containing metabo lites, however, is difficult and time consuming and therefore unsuitable for a screening method.
However, a specific and sensitive approach for tracing GSH conjugates and their degradation prod ucts can be performed by co-administration of un labelled drug and radioactive cysteine. The latter labels the GSH stores and related pathways in the organism [3, 4] , The specific and sensitive detection of such drug related products can then be conven iently established by application of modern HPLC techniques.
To find out scope and limitations, this approach was applied to the analgesic SX-PP 16. Since there are similarities to acetaminophen, its interaction with GSH was of superior interest. In addition, the investigation of SX-PP 16 was stimulated by the dis crepancy between the results of classical GSH deple tion studies and structure elucidation of its main bio transformation products.
Material and Methods
The drug SX-PP 16 (4-amino-3,5-dibromacetanilide) acts as an analgesic drug.
We used non-labelled and the 14C-labelled SX-PP 16 1 .49 x 108 Bq/mmol, uniformly labelled in the aromatic ring (Purity > 99%). 
Animals and dosing
For the studies male rats of 200 g body weight Chbb/Thom were used. Each animal received 100 |xCi labelled cysteine orally by gavage as an oxygen-free solution together with about 20 mg unlabelled cysteine. For the application of the drug a slurry of SX-PP 16 in 1% of TyloseR SL 400 was prepared in a concentration range of 5 to 30 mg/kg. The final application volume was in each case 1 ml. For collection of bile we used conscious (p.o.-dosing) and anesthesized (i.d.-dosing) animals.
The bile collection gadget used in conscious animals was prepared according to the method described by Tomlinson [5] .
Instruments

Mass spectrometry
The El mass spectra (70 eV) were recorded with a Kratos AEI MS 902 updated by VG Instruments (Manchester, GB) which was linked to an Incos data system (Finnigan, San Jose, USA). The samples were introduced via a direct inlet system and evapo rated by heating the source to 120-150 °C. The FAB mass spectra were performed using the same instru ment, provided with a VG FAB ion source of stand ard design. The samples were generally dissolved in 1-3 |^1 methanol and mixed with 3-5 |^1 glycerol on top of the stainless steel target to form a clear solu tion. The target was inserted into the ion source by a direct inlet system and bombarded with a 8-10 keV beam of Xenon atoms. The generated ions were ex tracted from the source and accelerated with 8 kV. The mass spectra were taken with scan rates of 10 or 15 sec/decade at a resolution of approximately 2000 (10% valley definition).
NMR spectroscopy
The !H NMR spectra were recorded in pulse Fourier transform mode using 80, and 400 MHz spec trometers of Bruker (Karlsruhe, FRG).
Deuterochloroform, d4-methanol and mixtures thereof served as solvents, whereas tetramethylsilane was used as an internal standard. The HPLC was used in two column-switching ar rangements.
A) The arrangement without quantifying the ex traction yield was built according to the equipment described by Roth [6] .
B) The fully automated equipment was built ac cording to Schmid [7] . It allows the quantification of the extraction yield. Briefly, the urine is loaded onto a precolumn, the precolumn is flushed with water containing 1% ammoniumacetat for 6 min. This ef fluent is monitored by radioactivity detection. After 6 min the content of the precolumn is transfered to the main column and the gradient program is started. The radioactivity detector is switched from the pre column to the main column to monitor the separa tion.
For profiling of body fluids 2 ml of urine or 0.5 ml of bile were injected onto the HPLC precolumn.
Isolation o f the main metabolite
The urine of the 0-24 h collection period (176 ml) was extracted with 12 g XAD-4, Rohm and Haas (Darmstadt, FRG). After washing with 240 ml wa ter, the XAD-4 was eluted with 370 ml methanol.
The organic phase was evaporated under reduced pressure. The residue was redissolved in 40 ml wa ter. This phase contained 92.1% of the original radioactivity and was separated in 15 runs with the gradient described above. The separated compounds were collected. The main metabolite was further ap The band of interest was scrapped with a spatula and the compound eluted with methanol/water 90:10. The extract was finally chromatographed on the HPLC system described above, however without acetic acid.
Results
Glutathione depletion study
The results of a classical GSH depletion study are depicted in Table I . SX-PP 16 has only a moderate influence on the depletion of GSH-stores. Table I . Glutathione depletion. Rats were dosed 2 h before the analysis of the organ with different doses of SX-PP 16. The GSH levels were determined according to Ellman [8] . 
Incorporation o f labelled cysteine into the SX-PP 16 molecule by biotransformation
The pattern of radioactivity in urine with 100 ^iCi [14C]cysteine alone and with co-administration of 30 mg/kg SX-PP 16 revealed additional peaks in the HPLC chromatogram at about 28-32 min (Fig. 2) . The peaks at a retention time of 3-8 min are appar ently due to endogenous reaction products of the administered cysteine (presumable taurine).
The result obtained with bile differs (Fig. 3) , as there are not only peaks at 2-7 min in the blanc but also a major group of peaks at 37-42 min.
However, the group of peaks at a retention time of 26-32 min is related to the co-administered drug. Rather the same pattern is observed when [35S] cysteine (100 |xCi) and 30 mg SX-PP 16 is dosed (Fig. 4) . The individual pattern in bile is rather simi lar in all five animals. The percentage of radioactivity excreted during the 2 -8 h period was 30.5% ± 6.60% (n = 5) of the dosed radioactivity.
On the other hand the pattern in urine is consistent in 4 of 5 animals. The percentage of radioactivity excreted during the 2-8 h period was 10.2% ± 0.53%. One animal with low excretion during this period caught up with the others during the following 8-26 h collection intervall. The first peaks between 3 and 8 min show very poor retention behaviour on the precolumn. They cannot be used for interpreta tion. This problem could be overcome, however, by changing the precolumn switching mode (HPLC method B, Materials and Methods).
Improving o f the detection limit
Low doses of the drug in question or formation of the corresponding GSH adducts in low yields only, give rise to problems concerning the radioactivity The peaks which were not in the blancs (without drug administration) are coloured black (HPLC method A).
and further identification of these products. This can be overcome by simultaneous diode array detection of the corresponding drug chromophor using the technique of isoabsorbance plots [17] .
In The principle of the isoabsorbance plot is illus trated in Fig. 6 . It shows the UV spectrum of SX-PP 16 together with the corresponding isoabsorbance plot obtained during an HPLC run.
The UV spectrum of SX-PP 16 is characterized by three maxima: 215 nm, 262 nm, 314 nm. The ab sorption maxima at longer wavelengths are more relevant for compound identification.
According to this technique the diode array trace of the retention region between 30-43 min is de picted in Fig. 7 . At approximately 31.5 min there is a signal as well in the UV plot as in the radioactivity traced chromatogram showing a typical picture of three maximas (220 nm, 262 nm and 320 nm). Thus the peak at 31.5 min should contain the chromophor of SX-PP 16. In contrast at a retention time of 40-43 min there is no indication for such an UV spectrum. Thus only the peak at 31.5 min should be related to S-eonjugates of SX-PP 16 but not the peaks between 40-43 min.
Timing o f cysteine and drug dosage
To evaluate the optimal timing of labelled cysteine and drug the following experiment was performed:
Rats received at zero time 100 fiCi [14C]cysteine and 2 h later 30 mg/kg SX-PP 16. At the second and third day again a dose of 30 mg/kg SX-PP 16 was administered but without predosing labelled cys teine. The results are shown in Fig. 8 . Thus the best sampling time providing the highest yield of labelled GSH conjugates is the time interval 2 -2 6 h after application of labelled cysteine.
Isolation and structure elucidation o f the main metabolite
To get a brief insight into the metabolic pattern of 14C-labelled SX-PP 16 we focused our attention to urine and bile only. At this point of investigation there was no need to perform a complete balance study including feces.
For the isolation of the metabolites 30 mg R e labelled SX-PP 16 was administered to 5 animals. The urinary and biliary excretion is summarized in Table II . Fig. 9 (top) represents the urinary pattern of the collection period 0-24 h p.a. The radioactivity in the retention range of 1-6 min is caused by not retained metabolites.
In Fig. 9 (bottom) the biliary pattern of the collec tion period 0-8 h p.a. is depicted.
The following results are apparent: There are only 15.4% of the parent compound (MO) in the urine and 4.3% in the bile. The metabolite M12 is the main metabolite in urine. It represents 46% of the excreted radioactivity. This metabolite is also present as the main peak in the metabolic pat- tern when labelled cysteine together with unlabelled SX-PP 16 is administered. This is also valid for the bile metabolites. After isolation and derivatization with diazomethane, structure elucidation of the main metabolite M12 could be performed by its El and FAB mass spectra and by its 'H NMR spectrum depicted in Fig. 10-12 . The El mass spectrum in Fig. 10 shows a very weak molecular ion at m/z 403/5 according to the presence of one bromine atom only. Its further breakdown which is also schematically outlined in Fig. 10 corresponds to that of 3-mercapturyl-acetaminophene [20] . FAB mass spectrometry confirmed the suggested mercapturic acid methylester in the abundant (M + H) ion m/z 404/6. The intense ion m/z 144 represents the structural moiety of the N-acetylated amino acid methylester as indi cated in Fig. 11 .
The proposed structure of a 3-bromo-4-amino-5-mercapturyl acetanilid for the metabolite M 12 is ful ly established by the *H NMR spectrum in Fig. 12 . The meta position of the two aromatic protons is indicated by the doublets (/' = 3 Hz) at 7.41 and 7.71 ppm respectively (Fig. 12, bottom) . 
Discussion
Methods which should be routinely used during pharmacokinetic and metabolic studies must be sen sitive, specific and convenient. At early stages of drug development an additional handicap arises in so far as these drugs are not available as a labelled com pound.
The interaction of a drug with GSH is mostly studied by its influence on the GSH levels of organs by colorimetric [8] or electrochemical [19] proce dures. These methods measure the decrease of the huge GSH stores and not the formation of drug GSH adducts. Our suggested approach for the specific and sensi tive detection of GSH conjugates and their degrada tion products by labelling the GSH stores in the organism, and administration of the unlabelled drug in therapeutical doses, has been convincingly per formed with the analgesic drug SX-PP 16. Thus, the pattern of radioactivity in urin of rats receiving 100 ^iCi [14C]cysteine alone or with co-administration of 30 mg/kg unlabelled SX-PP 16 revealed unambigiously additional peaks by comparison of the corre sponding HPLC chromatograms (Fig. 2) . The same result could be obtained with bile even though there are two groups of peaks in the HPLC chromatograms which are related to endogenous compounds (Fig. 3) . Both results could be verified by feeding the animals with 100 ^iCi [3:,S]cysteine (Fig. 4) indicating that there are no substantial differences between [14C]-and pSjcysteine in this case. However, using [35S]cysteine all sulfur containing metabolites of the drug can be detected.
Taking a time interval between dosing of radio active cysteine and the drug respectively, the possi bility arises of collecting urine and bile before drug administration. This means that an individual blanc can be obtained from each animal. As shown in Fig. 8 administration of SX-PP 16 2 h after cystein dosage still gives reasonable yields of drug conjugates in urine, collected in intervals of 2-8 and 8-26 h p. a. respectively. However, additional doses of SX-PP 16 one or two days later do not enhance the yields. This is in agreement with the observation of Lauterburg [4] and Tateishi [15] , who determined the hepatic GSH turn-over of the main pool to be about 1.5 h. The half-life of radioactivity excretion by urine is determined not only by the formation rate of the drug conjugates but also by their elimination charac teristics. In so far, the excretion of conjugate at late collection intervals can not be primarily attributed to the second GSH pool according to Tateishi [15] .
Principally it is a probleme to detect unknown structures with unknown chromatographic and spec troscopic behaviour. However, this can be overcome making use of the potencies of modern HPLC. From our experience with SX-PP 16 and other drugs a re versed phase C18 column with a gradient, ranging from acidic water to methanol is a reasonable choice to trace most of the metabolites like mercapturic acids generated by reaction of basic drugs with GSH. Very polar metabolites in urine and bile which are not retained on the precolumn, however, should be quantified too. The column switching unit (method B) allows to monitor the not retained fraction, and thus to quantify the extraction yield achieved by the HPLC precolumn automatically.
The sensitivity of the method is limited by the HPLC detection, since it is based on the differences between HPLC chromatograms of drug untreated (blanc) and treated animals (Fig. 2) . The coincidence of the radio signal and the drug characteristic UV signal (in our case 262 and 320 nm) enhances the probability of correct identification considerably since a GSH conjugation usually does not change the chromophor of a drug drastically. If there are further questions about the identity of the peak it might be collected and chromatographed in a different solvent system to a constant ratio of UV versus radioactivity signal.
Comparing the metabolic pattern regarded to the application of the 14C-labelled SX-PP 16 and un labelled drug together with labelled cysteine respec tively there is strong evidence that most of the metabolites of SX-PP 16 are formed by reaction of the drug with GSH. As the investigation was not performed to be a complete biotransformation study of this drug, we focused our attention on the main metabolite in urine. All our data are consistent with the structure of a mercapturic acid formed by sub stitution of one bromine atom (Fig. 12) .
The biological insertion of a sulfur containing moiety (above all GSH) into a drug is the result from nucleophilic attack at an electron deficient center [3, 9, 10, 16] .
In the case of SX-PP 16 the formation of the 5-mercapturic acid is thought to proceed via an electrophilic quinonimine intermediate. This is possibly generated by oxidation of the parent compound by cytochrome P-450/P-448 mediated monooxygenases.
This pathway is of particular interest, as the struc tural related quinonimines originated from 3,5-dimethylacetaminophen and the 2,6-dimethyl-isomer were studied with respect to GSH interaction [11, 18] . The 3,5-dimethyl compound (in contrast to the 2,6-isomer) did not produce any GSH adduct. The different behaviour of SX-PP 16 is attributed to the stabilization of a presumable formed GSH adduct by elimination of a bromide anion. On the other hand, substitution of aromatic bonded halogens by sulfurmoieties are not unusual, e.g. the chemicals chloronitrobenzenes, hexachlorobenzene [12] , the drugs flumezapine [13] and a pyrano-quinoline [14] . The outstanding high yield, however, in the case of SX-PP 16 is unexpected and remarkable.
All our findings concerning the incorporation of labelled cysteine into the SX-PP 16 molecule are in contrast to the results obtained by a classical GSH depletion study according to Ellmann [8] . We could detect only a moderate effect of SX-PP 16 on the GSH levels even at doses 10-40 times higher (Table  I) . These results mirror the general difficulties of all approaches taking changes of GSH levels in the organs of certain species into account. Since the turn over of GSH is comparable short (approximately 1-2 h) and different in different species the timing of the depletion measurements become ambigious regarding the time of drug application. In addition this situation is complicated by the fact that nothing is known about pharmacokinetics and disposition of the drug at this state of development. However, the complexity of such investigations is elegantly over come by the offered method of labelling the GSH stores. As far as SX-PP 16 is concerned there might be two additional explanations on hand for the only moderate depletion of GSH levels:
i The pathway yielding a quinonimine is mediated by enzymes which are saturable. In the case of SX-PP 16 there are indications that the cyto chromes P-448 subclass is involved in the biotrans formation of this compound. It is well-known that P-448 have a low contribution to total cytochrome content in non-induced rats, ii The absorption of SX-PP 16 might be incomplete at higher dosages as SX-PP 16 is rather insoluble in all application formulations tested so far.
In conclusion, we have shown that a drug/GSH interaction can be conveniently detected by labelling the GSH stores with labelled cysteine and subse quent tracing of the formed conjugates by modern HPLC techniques. Apparently this approach has the following advantages over a classical GSH depletion study: There is no ambiguousy regarded to the tim ing of the experiments. It is absolutely specific and more sensitive and it even works at therapeutic doses. Furthermore there are less animals needed and each animal can be used as its own control.
